Statement 1.5: Patients with worsening signs or symptoms of CD during treatment should undergo assessment for intestinal inflammation, using biomarkers, small bowel radiography, endoscopy or cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) (Evidence level 5)	Voting agreement rate 45/45 (100%)
Statement 1.6: Endoscopy is the established standard for the assessment of intestinal inflammation (Evidence level 5)	46/47 (97.9%)
Statement 1.7: It is important to visualize the small bowel mucosa, using balloon-assisted endoscopy or capsule endoscopy, when active small bowel disease is suspected (Evidence level 2a)	47/47 (100%)
Statement 1.8: When endoscopy or capsule endoscopy is not feasible or practical, noninvasive imaging using magnetic resonance enterography (MRE), CT enterography (CTE) or ultrasound is the preferred modality (Evidence level 5)	47/47 (100%)
Statement 1.9: CT use should be minimized in patients with CD to limit lifetime exposure to radiation (Evidence level 1a/1b)	47/47 (100%)